Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years, according to a congressional analysis. Expanding coverage of weight-loss ...
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Eight local high school seniors have been selected as finalists for next year’s Lilly Endowment Community Scholarships, which cover the full cost of a four-year college education. The highly ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.
Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...
In the first randomized controlled trial in patients with vestibular migraine, galcanezumab outperformed placebo in reducing ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...
Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half. What doesn’t it ...
STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback